DE60229371D1 - Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung - Google Patents

Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung

Info

Publication number
DE60229371D1
DE60229371D1 DE60229371T DE60229371T DE60229371D1 DE 60229371 D1 DE60229371 D1 DE 60229371D1 DE 60229371 T DE60229371 T DE 60229371T DE 60229371 T DE60229371 T DE 60229371T DE 60229371 D1 DE60229371 D1 DE 60229371D1
Authority
DE
Germany
Prior art keywords
activators
memory performance
improve learning
anhydrate
carbonic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60229371T
Other languages
English (en)
Inventor
Daniel Alkon
Miao-Kun Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blanchette Rockefeller Neuroscience Institute
Original Assignee
Blanchette Rockefeller Neuroscience Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blanchette Rockefeller Neuroscience Institute filed Critical Blanchette Rockefeller Neuroscience Institute
Application granted granted Critical
Publication of DE60229371D1 publication Critical patent/DE60229371D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
DE60229371T 2001-05-02 2002-05-02 Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung Expired - Fee Related DE60229371D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28772101P 2001-05-02 2001-05-02
PCT/US2002/013784 WO2002087423A2 (en) 2001-05-02 2002-05-02 Carbonic anhydrase activators for enhancing learning and memory

Publications (1)

Publication Number Publication Date
DE60229371D1 true DE60229371D1 (de) 2008-11-27

Family

ID=23104047

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60229371T Expired - Fee Related DE60229371D1 (de) 2001-05-02 2002-05-02 Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung

Country Status (9)

Country Link
US (1) US20040235889A1 (de)
EP (1) EP1383497B1 (de)
JP (1) JP4824268B2 (de)
AT (1) ATE411019T1 (de)
AU (1) AU2002256422A1 (de)
CA (2) CA2446074C (de)
DE (1) DE60229371D1 (de)
ES (1) ES2314056T3 (de)
WO (1) WO2002087423A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
WO2006020171A1 (en) * 2004-07-19 2006-02-23 University Of Florida Research Foundation, Inc. Methods and materials for treating mental illness
CA2864550C (en) 2007-02-09 2018-07-10 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury
EP3332797A3 (de) 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Therapeutische wirkungen von bryostatinen, bryologen und anderen damit zusammenhängenden substanzen auf durch kopftraumata herbeigeführte gedächtnisstörungen und hirnverletzungen
JP2016515138A (ja) * 2013-03-14 2016-05-26 ヤンセン ファーマシューティカ エヌ．ベー． Ｇｐｒ１３９の生理的リガンド

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
RO86393B1 (ro) * 1983-04-19 1985-04-01 Gheorghe Danila Medicament cu actiune vasculo-trombocitara
WO1985003869A1 (en) * 1984-03-01 1985-09-12 Vernon Erk Method of treating memory disorders of the elderly
US5962498A (en) * 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US6080784A (en) * 1986-06-11 2000-06-27 Procyon Pharmaceuticals, Inc. Protein kinase C modulators N
US5955501A (en) * 1986-06-11 1999-09-21 Procyon Pharmaceuticals, Inc. Protein kinase C modulators O
US6043270A (en) * 1986-06-11 2000-03-28 Procyon Pharmaceuticals, Inc. Protein kinase C modulators V
US5891906A (en) * 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Polyacetate-derived phorboids having anti-inflammatory and other uses
US4833257A (en) * 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
US5220068A (en) * 1986-09-25 1993-06-15 Chinoin Gyogyszer - Es Vegyeszeti Termekek Gyara Rt. Psychostimulant agent
HU207280B (en) * 1986-09-25 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5072004A (en) * 1990-12-31 1991-12-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthetic conversion of bryostatin 2 into bryostatin 1
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
US5196447A (en) * 1991-08-08 1993-03-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University Neristatin 1
US5359115A (en) * 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
DE4232899C2 (de) * 1992-09-30 1995-02-23 Birkmayer Joerg Univ Prof Dr Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer
US5393897A (en) * 1993-07-02 1995-02-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of spongistatins 5,7,8 and 9
US5362899A (en) * 1993-09-09 1994-11-08 Affymax Technologies, N.V. Chiral synthesis of alpha-aminophosponic acids
US5625232A (en) * 1994-07-15 1997-04-29 Texas Instruments Incorporated Reliability of metal leads in high speed LSI semiconductors using dummy vias
US6001998A (en) * 1994-11-10 1999-12-14 Pfizer Inc Macrocyclic lactone compounds and their production process
US5944021A (en) * 1995-06-07 1999-08-31 Rodriguez; Victorio C. Therapeutic use of a carbonic anhydrase enzyme inhibitor for the treatment of brain edema
RU2115653C1 (ru) * 1995-12-27 1998-07-20 Иркутский институт органической химии СО РАН Комплексные соединения замещенных имидазолов, проявляющие антидотную и антигипоксантную активность
US6043283A (en) * 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
IL134590A0 (en) * 1997-09-08 2001-04-30 Univ Georgetown Substituted 2-pyrrolidinone activators of pkc
US5972684A (en) * 1997-11-25 1999-10-26 Incyte Pharmaceuticals, Inc. Carbonic anhydrase VIII
EP2338482A3 (de) * 1998-04-14 2011-12-21 The General Hospital Corporation Verfahren zur Behandlung neuropsychischer Erkrankungen
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
AU772054B2 (en) * 1999-04-30 2004-04-08 Nathan S. Kline Institute For Psychiatric Research, The Methods for the identification of compounds for the treatment of alzheimer's disease
WO2001093744A2 (en) * 2000-06-07 2001-12-13 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Controlling attention and memory by altering neuronal carbonic anhydrase activity
US6933074B2 (en) * 2001-07-19 2005-08-23 Wilson Greatbatch Technologies, Inc. Insulative component for an electrochemical cell
TW201207390A (en) * 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity

Also Published As

Publication number Publication date
AU2002256422A1 (en) 2002-11-11
ATE411019T1 (de) 2008-10-15
WO2002087423A2 (en) 2002-11-07
WO2002087423A3 (en) 2003-02-27
ES2314056T3 (es) 2009-03-16
CA2446074C (en) 2011-09-06
JP2004535386A (ja) 2004-11-25
EP1383497B1 (de) 2008-10-15
EP1383497A2 (de) 2004-01-28
CA2744115A1 (en) 2002-11-07
EP1383497A4 (de) 2005-12-14
US20040235889A1 (en) 2004-11-25
CA2446074A1 (en) 2002-11-07
JP4824268B2 (ja) 2011-11-30

Similar Documents

Publication Publication Date Title
DE60132709D1 (de) Bestimmung der wirksamen zusammensetzung von kohlenwasserstoffgasen
DE60319443D1 (de) Zusammenbau von chirurgischem Klammerwerkzeug
DE60038409D1 (de) Rückgewinnung von Kohlendioxyd aus einem Sauerstoffhaltigen Gemisch
DE60210904D1 (de) Nitrit-stabilisierte Zusammensetzungen von Tetrazolium-Reagenz und Methoden derer Nutzung
DE602004023229D1 (de) Mais metallothionen promoter 2 und methoden zur verwendung
ID29380A (id) Penhilangan konstituen gas asam dari gas
DE60238035D1 (de) Cystinderivate und inhibitoren zur aktivierung von entzündungsfaktoren
EA200801534A1 (ru) 3`-алкоксиспироциклопентилзамещенные тетрамовые и тетроновые кислоты
DE60126226D1 (de) Katalysator zur Reinigung von Abgasen
DE60331199D1 (de) Trennung und rückgewinnung von bor
DE60330341D1 (de) Verfahren zur herstellung von wabenstrukturen
NO20014495L (no) Ny anordning for oksygenering av sjövann
BRPI0414463A (pt) ácidos heteroarilbenzofuránicos substituìdos
DE60126814D1 (de) Inhalation von stickoxid
DE60307710D1 (de) Verfahren zur Herstellung von Eisenoxiden
DE50302818D1 (de) Zubereitungen zur topischen applikation von antiandrogen wirksamen substanzen
DE60222042D1 (de) Herstellungsverfahren von Fahrzeugkarosserie-Seitenwänden
DE60229371D1 (de) Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung
DE60300548D1 (de) Katalysator zur Reinigung von Abgasen
DE60319764D1 (de) Kontrolle von Kohlenwasserstoffbohrungen
DE602004004943D1 (de) Reinigung von Metallkohlenwasserstoff
EP1499586A4 (de) Neue form von n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanin
DE60223718D1 (de) Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
ATE513041T1 (de) Ghrelin bindende nukleinsäuren

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE, US

8364 No opposition during term of opposition
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Ref document number: 1383497

Country of ref document: EP

Effective date: 20111201